Document is current
Any future updates will be listed below
-
Authors
Escarrat, Vincent
Reato, Davide
Blivet, Guillaume
Touchon, Jacques
Rougon, Geneviève
Bos, Rémi
Debarbieux, Franck
-
Funding
Funding for this research was provided by:
Agence Nationale pour la Recherche Technologique (CIFRE)
REGEnLIFE
Agence Nationale de la Recherche (18-CE19-0029-02)
Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques (1248)
IUF
- License Information
-
More Information
Article History
Received: 2 September 2024
Accepted: 11 November 2024
First Online: 18 December 2024
Declarations
:
: All experimental procedures were performed in accordance with the French legislation and in compliance with the European Community Council Directive of November 24, 1986 (86/609/EEC), for the care and use of laboratory animals. The research was authorized by the Direction Départementale des Services Vétérinaires des Bouches-du-Rhône (license D-13-055-21) and approved by the National Committee for Ethics in Animal Experimentation and the local ethics committee (Comité d’Ethique en Neurosciences INT-Marseille, CE71 Nb A1301404 [project authorization APAFIS#31909 and CE14 project authorization APAFIS#30760]).
: G. B. is a member of the company REGEnLIFE and owns equity. J. T. is a consultant for REGEnLIFE. V.E., D. R., G. R., R. B., and F.D. are members of AMU and declare that they have no financial interests that could be perceived as being a conflict of interest or to influence the work reported in this paper.
